These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 22675625)

  • 61. Targeted therapy of metastatic breast cancer.
    Sánchez-Muñoz A; Pérez-Ruiz E; Jiménez B; Ribelles N; Márquez A; García-Ríos I; Alba Conejo E
    Clin Transl Oncol; 2009 Oct; 11(10):643-50. PubMed ID: 19828406
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Advances in chemotherapy for colorectal cancer.
    Bernold DM; Sinicrope FA
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):808-21. PubMed ID: 16797250
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combining emerging agents in advanced breast cancer.
    Luu T; Chung C; Somlo G
    Oncologist; 2011; 16(6):760-71. PubMed ID: 21543509
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Molecular biology in clinical cancer research: the example of digestive cancers].
    Lièvre A; Laurent-Puig P
    Rev Epidemiol Sante Publique; 2005 Jun; 53(3):267-82. PubMed ID: 16227914
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.
    Blank PR; Dedes KJ; Szucs TD
    Pharmacoeconomics; 2010; 28(8):629-47. PubMed ID: 20524722
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intermittent therapy in the palliative treatment of metastatic colorectal cancer.
    Wadhawan A; Stephens R; Adams R
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):125-34. PubMed ID: 19105712
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeted therapies: a new generation of cancer treatments.
    Gerber DE
    Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955
    [TBL] [Abstract][Full Text] [Related]  

  • 69. TNFRSF10C copy number variation is associated with metastatic colorectal cancer.
    Tanenbaum DG; Hall WA; Colbert LE; Bastien AJ; Brat DJ; Kong J; Kim S; Dwivedi B; Kowalski J; Landry JC; Yu DS
    J Gastrointest Oncol; 2016 Jun; 7(3):306-14. PubMed ID: 27284460
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Current treatments and future perspectives in colorectal and gastric cancer.
    Wilke HJ; Van Cutsem E
    Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Second-line therapy for advanced colorectal carcinoma.
    Starling N; Cunningham D
    Curr Oncol Rep; 2005 May; 7(3):173-80. PubMed ID: 15847707
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream.
    Goel G
    Cancer Manag Res; 2018; 10():5895-5908. PubMed ID: 30510457
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Colorectal cancer: Review of signaling pathways and associated therapeutic strategies.
    Leiphrakpam PD; Rajappa SJ; Krishnan M; Batra R; Murthy SS; Are C
    J Surg Oncol; 2023 Jun; 127(8):1277-1295. PubMed ID: 37222698
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The impact of somatic SMAD4 mutations in colorectal liver metastases.
    Xourafas D; Mizuno T; Cloyd JM
    Chin Clin Oncol; 2019 Oct; 8(5):52. PubMed ID: 31500428
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential Role of Traditional Chinese Medicines by Wnt/β-Catenin Pathway Compared With Targeted Small Molecules in Colorectal Cancer Therapy.
    Chang J; Xavier HW; Chen D; Liu Y; Li H; Bian Z
    Front Pharmacol; 2021; 12():690501. PubMed ID: 34381360
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
    Hurwitz H
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
    Hanna DL; Lenz HJ
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.